Biogen

BIIB

Market cap $30.4B

BIIB Hedge Fund Activity: Q1 2026 in Review

1,002 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2026, worth a combined $24.7B — up 0.55% from $24.6B a quarter earlier.

Buyers outnumbered sellers: 134 funds opened new BIIB positions and 106 closed out — a net gain of 28 holders — while 398 added to existing stakes and 290 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $623M. The largest seller was Point72 Asset Management, cutting an estimated $369M.

• 1,002 institutional investors held Biogen (BIIB) as of Q1 2026, up from 997 in Q4 2025.
• Funds reported $24.7B of Biogen stock for Q1 2026, up 0.55% quarter-over-quarter.
• 134 funds opened new Biogen positions in Q1 2026 and 106 closed out, a net change of +28 holders.
• The largest Biogen buyer in Q1 2026 was Fidelity Investments, an estimated $623M added.
• The largest Biogen seller in Q1 2026 was Point72 Asset Management, an estimated $369M sold.

Based on aggregated 13F filings for Q1 2026.